Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBT 011

Drug Profile

NBT 011

Alternative Names: ABI-011; IDN 5404; IND-5404; nab-5404; nab-IND-5404; NTB-011

Latest Information Update: 18 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abraxis BioScience; Indena
  • Developer NantBioScience
  • Class Antineoplastics; Colchicum alkaloids; Drug conjugates
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 08 Jan 2018 Phase-I clinical trials in Lymphoma (Late-stage disease) in USA (IV) (NCT02582827)
  • 08 Jan 2018 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT02582827)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top